Julien Seneschal

Employment

• University of Bordeaux Professor in Dermatology
  2010 - Present

Education

• Université de Bordeaux Professor
  2015 - Present

Projects & Funding

Projects & funding information is unavailable.

Publications (148)

• Assessing the content validity of the 2015 core domain set for vitiligo clinical trials: preliminary investigations for developing an updated version
  Skin Health and Disease 2026 DOI: 10.1093/skinhd/vzag150
  +Save
• Early systemic intervention for vitiligo: A prospective bicentric interventional study
  Journal of the European Academy of Dermatology and Venereology 2026 DOI: 10.1111/jdv.70748
  +Save
• Rapid efficacy of anifrolumab in refractory cutaneous dermatomyositis
  Journal of the European Academy of Dermatology and Venereology 2026 DOI: 10.1111/jdv.70580
  +Save
• Shining a light on Jak inhibition: Partnering with NB-UVB to drive repigmentation in vitiligo
  Journal of Investigative Dermatology 2026 DOI: 10.1016/j.jid.2026.01.002
  +Save
• Suicidal ideation in patients with atopic dermatitis: A case‐control study on 23,191 adults
  Journal of the European Academy of Dermatology and Venereology 2026 DOI: 10.1111/jdv.70138
  +Save
• Clinical heterogeneity in vitiligo: Identification of clinical markers based patient clusters
  Journal of the European Academy of Dermatology and Venereology 2026 DOI: 10.1111/jdv.20785
  +Save
• Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND
  Dermatology and Therapy 2026 DOI: 10.1007/s13555-026-01656-7
  +Save
• Defining Important Aspects of Repigmentation in Vitiligo: Insights From Patients' Perspectives
  Pigment Cell & Melanoma Research 2026 DOI: 10.1111/pcmr.70078
  +Save
• Personalized medicine in vitiligo: A guide for daily practice
  Journal of the European Academy of Dermatology and Venereology 2026 DOI: 10.1111/jdv.70133
  +Save
• Evaluation of the repigmentation of facial vitiligo using an AI algorithm in a phase 2 study
  Journal of the European Academy of Dermatology and Venereology 2026 DOI: 10.1111/jdv.20798
  +Save
• 3D Imaging for Facial Vitiligo: Results From a Phase 2 Randomized Controlled Trial Investigating Upadacitinib in Patients With Vitiligo
  Journal of Investigative Dermatology 2026 DOI: 10.1016/j.jid.2025.12.036
  +Save
• Confetti-Like Lesions Surrounding Hair Follicles
  2026 DOI: 10.1007/978-3-032-28141-8_1
  +Save
• Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin
  Science Advances 2025 DOI: 10.1126/sciadv.adu9360
  +Save
• Vitiligo
  Nature Reviews Disease Primers 2025 DOI: 10.1038/s41572-025-00670-x
  +Save
• Regulatory T Cell Dysregulation in Vitiligo: A Meta‐Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives
  International Journal of Dermatology 2025 DOI: 10.1111/ijd.17959
  +Save
• Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
  Journal of the European Academy of Dermatology and Venereology 2025 DOI: 10.1111/jdv.20657
  +Save
• Refractory anogenital Hailey‐Hailey disease successfully treated with topical ruxolitinib
  Journal of the European Academy of Dermatology and Venereology 2025 DOI: 10.1111/jdv.20620
  +Save
• Unveiling the Unseen: Exploring Cellular Dynamics in Nonlesional Vitiligo Skin
  Journal of Investigative Dermatology 2025 DOI: 10.1016/j.jid.2025.01.033
  +Save
• Alopecia areata and ritlecitinib: Unravelling response trajectories
  Journal of the European Academy of Dermatology and Venereology 2025 DOI: 10.1111/jdv.20686
  +Save
• Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies
  Dermatology and Therapy 2025 DOI: 10.1007/s13555-025-01381-7
  +Save